M&A Deal Summary

Akari Therapeutics Acquires Peak Bio

On March 5, 2024, Akari Therapeutics acquired life science company Peak Bio

Acquisition Highlights
  • This is Akari Therapeutics’ 1st transaction in the Life Science sector.
  • This is Akari Therapeutics’ 1st transaction in the United States.
  • This is Akari Therapeutics’ 1st transaction in California.

M&A Deal Summary
Date 2024-03-05
Target Peak Bio
Sector Life Science
Buyer(s) Akari Therapeutics
Deal Type Merger
Advisor(s) DLA Piper (Legal)

Target

Peak Bio

Pleasanton, California, United States
Peak Bio is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing significant unmet needs in the areas of oncology and inflammation. Peak Bio is based in Pleasanton, California.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Akari Therapeutics

London, New York, United Kingdom
Category Company
Sector Life Science
Employees9
DESCRIPTION

Akari Therapeutics is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, in particular those where the complement system or leukotrienes or both complement and leukotrienes together play a primary role in disease progression. Akari Therapeutics is headquartered in London, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Merger) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal